Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company follows an asset-light business model and outsources manufacturing to third-party WHO-GMP certified manufacturers. It earns revenue through sales of pharmaceutical formulations across multiple therapeutic segments including cardiology, orthopedics, pediatrics, critical care, wellness, gastroenterology, and neurology. The company also earns income through material supply and procurement support services.

Goldline Pharmaceutical an Book Built Issue, amounting to ₹ 11.61 Crore,consisting entirely an fresh issue of 0.27 crore shares of  ₹ 11.61 crores.The subscription period for the Goldline Pharmaceutical IPO opens on May 12, 2026, and closes on May 14, 2026. The allotment is expected to be finalized on or about May 15 2026, Friday, and the shares will be listed on the BSE SME with a tentative listing date set on or about Tuesday, May 19, 2026.

The Share Price Band of Goldline Pharmaceutical IPO is set at ₹41 to ₹43 per share  per equity share. The Market Capitalisation of the Goldline Pharmaceutical at IPO price of ₹43  per equity share will be ₹ 41.28 Cr. The lot size of the IPO is 3,000 shares. Retail investors are required to invest a minimum of ₹ 258,000,  2 lots ( 6,000 shares), while the minimum investment for High-Net-Worth Individuals (HNIs) is 3 lots ( 9,000 shares), amounting to ₹ 387,000.

CUMULATIVE CAPITAL PRIVATE LIMITED, the book running lead manager of the Goldline Pharmaceutical. while BIGSHARE SERVICES PRIVATE LIMITED is the registrar for the issue.The Market Maker of the company is Nirman Share Brokers Private Limited.

Goldline Pharmaceutical Limited IPO GMP Today
The Grey Market Premium of Goldline Pharmaceutical IPO is expected to be ₹0 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.

Goldline Pharmaceutical Limited IPO Live Subscription Status Today: Real-Time Update
The subscription period for the Goldline Pharmaceutical IPO opens on May 12, 2026,

Goldline Pharmaceutical Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Goldline Pharmaceutical IPO allotment date is May 15 2026, Friday, Goldline Pharmaceutical IPO Allotment will be out on May 15 2026, Friday, and will be live on Registrar Website from the allotment date.
BIGSHARE SERVICES PRIVATE LIMITED IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Goldline Pharmaceutical IPO from the dropdown list of IPO
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.

Objectives of Goldline Pharmaceutical Limited IPO
Goldline Pharmaceutical to utilise the Net Proceeds towards the following objects:
1. ₹835.45 Lakhs is required for Repayment of all or a portion of certain outstanding borrowings availed by our company
2. General Corporate Expenses

Refer to Goldline Pharmaceutical Limited RHP for more details about the Company.